Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial.

Blood - 18 Feb 2021

Le Gouill Steven, Morschhauser Franck, Chiron David, Bouabdallah Krimo, Cartron Guillaume, Casasnovas Olivier, Bodet-Milin Caroline, Ragot Sylviane, Bossard Céline, Nadal Nathalie, Herbaux Charles, Tessoulin Benoit, Tchernonog Emmanuelle, Rossi Cédric, McCulloch Rory, Gastinne Thomas, Callanan Mary B, Rule Simon

Abstract excerpt

Ibrutinib, obinutuzumab, and venetoclax demonstrate synergy in preclinical models of mantle cell lymphoma (MCL). OAsIs (NCT02558816), a single-arm multicenter prospective phase 1/2 trial, aimed to determine the maximum tolerated dose of venetoclax in combination with fixed doses of ibrutinib and obinutuzumab, in relapsed MCL patients. At the venetoclax MTD, extension cohorts were opened for relapsed and untreated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bridged Bicyclo Compounds, Heterocyclic
Share to Hematologic Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunoglobulin Variable Region

Share to Lymphoma, Mantle-Cell

Share to Maximum Tolerated Dose

Share to Neoplasm, Residual

Share to Piperidines

Share to Progression-Free Survival

Source

Identifiers

PMID: 33181832
DOI: 10.1182/blood.2020008727

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial.PMID 33181832Read ↗

Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.Semantic proximity Read ↗

Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial.Semantic proximity Read ↗

Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.Semantic proximity Read ↗

Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study.Semantic proximity Read ↗

Novel treatment for mantle cell lymphoma - impact of BTK inhibitors and beyond.Semantic proximity Read ↗

Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRDSemantic proximity Read ↗

Rocbrutinib in Covalent BTK Inhibitor Exposed Relapsed or Refractory Mantle Cell Lymphoma: a Phase 2, Open-label, Multicenter, Single-arm StudySemantic proximity Read ↗

Comparison Between Venetoclax-based and Bruton Tyrosine Kinase Inhibitor-based Therapy as Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Network Meta-analysis.Semantic proximity Read ↗

A Phase I Study using Bortezomib (Velcade), Cladribine, and Rituximab (VCR) in Treating Elderly Patients with Mantle Cell LymphomaSemantic proximity Read ↗

Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphomaSemantic proximity Read ↗

Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell LymphomaSemantic proximity Read ↗

Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agentsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.